Teams - Link provided in reminder email the day before the event
Innovative medical treatments have saved a lot of patients’ lives, but are usually very expensive. This situation will become more severe when the treatment becomes personalized. With drugs and medical treatments tailored to a subgroup of patients, their prices will inevitability be pushed up even further. Given the hundreds of new targeted therapies and diagnostics in development, there simply is not enough time and money for us to conduct drug development in the traditional way. Here we proposed a new business model for precision medicine. Early attempt of this business model, such as the Operation Warp Speed for COVID-19 vaccine, has successfully slashed the time of drug discovery and keep the price under control.
About the Speaker
Qianru (Cheryl) Qi is an Assistant Professor of Finance at the Telfer School of Management, University of Ottawa. Before joining Telfer, she has conducted research and teaching at Fudan University, New York University, and Duke University. She received her PhD in Financial Economics from the Krannert School of Management at Purdue University. She got her master’s degree in applied mathematics from the University of Kaiserslautern, Germany and her bachelor’s degree from Beijing Normal University, China.
Professor Qi’s research mainly focuses on financial technology, healthcare finance, banking and financial intermediation, and corporate finance. Her papers have been published in journals such as Management Science and Journal of Financial and Quantitative Analysis.
Register
Unfortunately, the RSVP deadline has passed for this event, and you will not be able to register.
